Early dermoscopic and confocal features predict response to topical ruxolitinib in nonsegmental vitiligo: A prospective observational study - 09/12/25
, Emanuela Martina, MD a, Aldo Gardini, PhD e, Tommaso Bianchelli, MD b, Giovanni Marco D'Agostino, MD b, Agnese Rossi, MD a, Emi Dika, MD, PhD c, d, Anna Campanati, MD aKey words : JAK inhibitors, reflectance confocal microscopy, ruxolitinib, vitiligo
| Drs Gioacchini, Veronesi, Dika, and Campanati contributed equally to this work. |
|
| Funding sources: None. |
|
| Patient consent: The patients were informed about the use of their clinical information according to the Declaration of Helsinki principles and photos for a publication intent. The informed consents were appropriately obtained during the medical examination. |
|
| IRB approval status: Not applicable. |
|
| Data availability statement: The data that support the findings of this study are available on request from the corresponding author. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
